

Publications 2015

(Actualisé / Up to date: Dec-15)

Equipe de Recherche / Research Team

Immunité et immunogénétique antivirale et vaccinale / Immunity and immunogenetics against viruses and vaccines

Chef d'équipe / Team Leader

Prof. Brigitte AUTRAN

1. Hattab S, Guiguet M, **Carcelain G**, Fourati S, **Guihot A**, **Autran B**, Caby F, Marcelin AG, Costagliola D, Katlama C. [Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.](#) HIV Med. 2015 Oct;16(9):553-62
2. Uttayamakul S, Oudot-Mellakh T, Nakayama EE, Tengtrakulcharoen P, Guergnon J, Delfraissy JF, Khusmith S, Sangsajja C, Likanonsakul S, **Theodorou I**, Shioda T. [Genome-Wide Association Study of HIV-Related Lipoatrophy in Thai Patients: Association of a DLGAP1 Polymorphism with Fat Loss.](#) AIDS Res Hum Retroviruses. 2015 Aug;31(8):792-6.
3. Sultanik P, Mallet V, Lagaye S, Casrouge A, Dorival C, Barthe Y, Fontaine H, Hézode C, Mottez E, Bronowicki JP, Carrat F, **Theodorou I**, Abel L, Gayat E, Fontanet A, Pol S, Albert ML; ANRS CO20-CUPLIC. [Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.](#) Liver Int. 2015 Jul;35(7):1833-44.
4. K Dorgham, Z Amoura, C Parizot, L Arnaud, C Frances, C Pionneau, **R Zoorob**, M Miyara, M Larsen, H Yssel, G Gorochov, A Mathian. [UV light converts propranolol, a lupus-inducing drug, into a pro-inflammatory AhR ligand.](#) Eur J Immunol. 2015, Sep 10
5. **Bourgarit A**, Baron G, Breton G, Tattevin P, Katlama C, Allavena C, Campa P, Ravaud P, Lortholary O, **Carcelain G**; IGRAVIH Study Group. [Latent Tuberculosis Infection Screening and 2-Year Outcome in Antiretroviral-Naive HIV-Infected Patients in a Low-Prevalence Country.](#) ANN; Am Thorac Soc., 2015 Aug;12(8):1138-45
6. **Guihot A**, Dentone C, Assoumou L, Parizot C, Calin R, Seang S, Soulié C, Marcelin AG, Calvez V, **Autran B**, Katlama C, Costagliola D, **Carcelain G**. [Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia.](#) AIDS. 2015 Jul 17.
7. Campillo-Gimenez L, Assoumou L, Valantin MA, Pajanirassa P, Villemonteix J, Soulié C, Marcelin AG, Costagliola D, Capeau J, **Autran B**, Katlama C, **Guihot A**; the ROCnRAL ANRS 157 Study Group. [Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia.](#) AIDS. 2015 Apr 24;29(7):853-6.
8. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, **Autran B**, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F. [Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure.](#) Gut. 2015 Feb 10. pii: gutjnl-2014-308943..
9. **Goulenok T**, Boyd A, **Larsen M**, **Fastenackels S**, **Boccaro F**, Meynard JL, Hadour N, **Samri A**, Desvarieux M, **Autran B**, **Appay V**, Girard PM, **Sauce D**; CHIC Study group. [Increased carotid intima-media thickness is not associated with T-cell activation nor with cytomegalovirus in HIV-infected never-smoker patients.](#) AIDS. 2015 Jan 28;29(3):287-93.